Evidence map›Paper›PMID 42536333›Full record

ArticleJapanese journal of ophthalmology2026

Six-month outcomes with a reduced two-injection induction (2+TAE) regimen of aflibercept 8 mg in treatment-naive neovascular age-related macular degeneration.

Nozomu Hashiya, Ichiro Maruko, Koji Tanaka, Junichiro Honjo, Yasunori Miyara, Yuto Watanabe, Ruka Maruko, Ayaka Nakai, Yu Wakatsuki, Kanako Itagaki and 10 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Nozomu HashiyaDepartment of Ophthalmology, Tokyo Women's Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Ichiro MarukoDepartment of Ophthalmology, Tokyo Women's Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo, 162-8666, Japan. imaruko@twmu.ac.jp.ORCID http://orcid.org/0000-0001-5647-6372
Koji TanakaDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Junichiro HonjoDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Yasunori MiyaraDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Yuto WatanabeDepartment of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.
Ruka MarukoDepartment of Ophthalmology, Tokyo Women's Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Ayaka NakaiDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Yu WakatsukiDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Kanako ItagakiDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Marina MaehiraDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Nobuhiro TeraoDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Keiko KataokaDepartment of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.
Annabelle A OkadaDepartment of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.
Hideki KoizumiDepartment of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Ryo MukaiDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Tetsuju SekiryuDepartment of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
Ryusaburo MoriDepartment of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
Tomohiro IidaDepartment of Ophthalmology, Tokyo Women's Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Japan AMD Research Consortium (JARC)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate 6-month outcomes of aflibercept 8 mg administered with two monthly injections followed by a treat-and-extend (TAE) regimen in treatment-naïve neovascular age-related macular degeneration (nAMD). STUDY

designMulticenter retrospective study.

methodsThis study included 107 treatment-naïve eyes with nAMD, of which 91 eyes of 90 patients (mean age, 74.7 ± 9.4 years) followed for 6 months were analyzed. All eyes received two consecutive monthly injections of aflibercept 8 mg (induction), followed by TAE. Best-corrected visual acuity (BCVA, logMAR), optical coherence tomography (OCT)-based anatomical outcomes, and adverse events were assessed.

resultsSixteen eyes were excluded, mainly due to being lost-to-follow-up or having had treatment changed to an alternative drug. No serious adverse events were observed. Mean BCVA improved from 0.43 ± 0.36 at baseline to 0.37 ± 0.42 at 6 months (P = 0.032). Retinal thickness, pigment epithelial detachment height, and subfoveal choroidal thickness significantly improved (all P < 0.05). The mean number of injections over 6 months was 3.4 ± 0.5, and the mean treatment interval at the end of 6 months was 11.6 ± 2.2 weeks. A dry macula was achieved in 70.3% of eyes, with a higher rate in eyes achieving a dry macula after a two-injection induction than in those requiring a three-injection induction (80.0% vs 51.6%, P < 0.01).

conclusionsEyes achieving a dry macula after two injections had higher 6-month dry rates than those requiring a third injection. Early treatment response may help predict treatment burden and guide individualized management strategies.

Indexed as

Aflibercept 8 mgNeovascular AMDTreat-and-extend

Identifiers

PMID42536333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.